Articles tagged with Positron Emission Tomography
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.
Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.
Researchers developed new imaging approaches using specialized amino acid PET tracers to visualize aggressive breast, lung, and glioma cancers. The studies showed promising results, highlighting the potential of these tools for future cancer imaging and guiding targeted therapies.
Researchers have developed new PET imaging tracers to detect and treat colorectal, thyroid, and lymphoma cancers. The tracers enable targeted radiation delivery, personalized dosing, and improved detection of inflammation in large blood vessels and liver lesions.
Researchers at Virginia Tech have developed a new method for attaching fluorine-18 to trifluoromethyl groups, enabling the tagging of previously inaccessible targets in PET scans. This breakthrough expands the range of molecules that can be imaged, potentially leading to earlier diagnoses and more targeted treatments for diseases.
Recent studies explored novel biomarkers for kidney cancer spread detection, heart scans for ATTR amyloidosis diagnosis, and radiation therapy delivery for neuroendocrine tumors. Additionally, researchers developed a new PET tracer to track heart-healing cells after a heart attack.
A prospective multicenter trial validated an improved method for predicting treatment benefits in hormone receptor-positive metastatic breast cancer with bone metastases. Metabolic change assessed by FDG-PET/CT accurately predicted progression-free survival as early as 12 weeks after treatment initiation.
Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...
A new study published at the Radiological Society of North America annual meeting found that individuals with obesity have a 95% faster increase in Alzheimer's disease biomarkers compared to non-obese individuals. Blood tests were more sensitive than PET scans in capturing the impact of obesity on Alzheimer's pathology.
A new study by UC San Francisco combines genetic risk with cardiovascular disease risk factors to predict who is more likely to develop dementia. The expanded view may help those worried about dementia, as lifestyle changes and improved control of illnesses can reduce brain damage and potentially delay or prevent symptoms.
Several studies examine imaging tools for detecting prostate cancer, testing new PET tracers for spotting aggressive tumors. Researchers also explored a new scan to detect gastrointestinal stromal tumors and improved imaging agents for pancreatic cancer diagnosis.
Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...
Researchers developed a detailed kidney model to study radiation distribution, highlighting uneven exposure across different nephron types. Tumor volume changes and PSMA PET imaging also showed promise for predicting outcomes in prostate cancer patients. New targeted therapies and imaging strategies aim to improve diagnosis and treatment.
Researchers have developed a new PET imaging agent that can distinguish true tumor response from inflammation during immune checkpoint inhibitor therapy. This breakthrough has the potential to improve early treatment assessment and patient outcomes.
A new approach to PET imaging can identify patients at risk of poor functional recovery after a heart attack by visualizing CXCR4, a cellular protein involved in inflammation. This technique enables timely implementation of treatments to mitigate inflammation and prevent heart failure progression.
Recent studies published in The Journal of Nuclear Medicine explore the use of artificial intelligence to improve PSMA PET/CT scan interpretation, as well as its impact on treatment decisions for patients with recurrent prostate cancer. Brain metabolic changes and fibroblast activation protein (FAP) PET imaging also reveal new insights...
MetaSeg achieves the same segmentation performance as U-Nets but requires 90% fewer parameters, making medical image segmentation more cost-effective. The new approach leverages implicit neural representations to quickly adjust to new images and decode accurate labels.
Studies have found that men with advanced prostate cancer can benefit from continuing PSMA therapy despite early PSA rise, while a new PET/CT scan may improve surgery decisions in pancreatic cancer. Molecular imaging advancements also hold promise for distinguishing aggressive kidney cancers and guiding treatment decisions.
Recent studies published in The Journal of Nuclear Medicine have made significant breakthroughs in prostate cancer treatment, with multiple therapies showing promise. Researchers have also discovered ways to reduce radiation exposure in PET scans and tracked the effects of alpha therapy on patients.
Researchers have developed promising therapies for advanced prostate cancer, improved brain imaging capabilities, and enhanced liver cancer detection. A new alpha therapy shows promise in treating thyroid cancer, while AI-assisted tracking systems enhance prognosis prediction in prostate cancer imaging.
A $10-million grant from the Weston Family Foundation will fund a project at McGill University to discover new Alzheimer's biomarkers. The ultra-high-sensitivity whole body PET/CT scanner, Panorama GS, will aid in understanding disease progression and developing personalized therapies.
A new PET tracer, 64Cu-NOTA-EV-F(ab′2), has been developed for same-day imaging of triple-negative breast and urothelial bladder cancers. The tracer exhibits rapid tumor accumulation and high specificity in nectin-4 positive tumors, enabling accurate non-invasive visualization of this protein.
Faster PET scans show promise for detecting liver inflammation and metabolic dysfunction-associated steatohepatitis. An AI tool combines multiple PET scans to integrate data from different tracers, improving disease insights. New imaging techniques enhance breast cancer surgery and predict recovery after heart attack.
New PET imaging agents show promise for detecting thyroid and neuroendocrine tumors, as well as reversing fibrosis in the heart. Researchers also explored tau PET scans for Alzheimer's detection and SSTR PET/CT for meningioma diagnosis. These advancements hold potential for improving cancer treatment and patient outcomes.
Researchers developed a new PET tracer that effectively identifies synapse loss in the spinal cord and brain after spinal cord injury. The study found reduced uptake of the tracer at the injury site and in the amygdala and cerebellum, suggesting potential for diagnosing and monitoring spinal cord injuries.
A new study from the University of Turku found that AI systems can accurately evaluate social features from images and videos, comparable to human evaluations. The researchers compared AI's evaluations with those made by over 2,000 humans, showing that AI's results were consistently accurate.
Researchers have developed new PET tracers to monitor immune responses and inflammation beyond the lungs throughout the course of SARS-CoV-2 infection. These breakthroughs offer a new way to visualize changes in lymph nodes, spleen, and bone marrow, supporting faster and more comprehensive imaging.
Researchers are using total-body PET imaging to investigate the relationship between long COVID symptoms and activated immune T cells, as well as blood vessel damage. The goal is to gain a better understanding of how these processes are related and how they contribute to long COVID symptoms.
Researchers have published three studies using new imaging approaches to detect and treat various types of cancer. These advancements include positronium lifetime tomography for sharper scans, targeted radiotherapy for sarcoma patients, and biomarkers for endometrial cancer diagnosis.
Recent studies have shown promising results for triple-targeted cancer therapy, new PET imaging tracers tracking immune activation, and reducing PET scan doses while maintaining diagnostic accuracy. These advancements hold promise for improving cancer treatment outcomes and precision medicine.
A new study from Denmark shows that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to those who do not. This research confirms that PSMA PET/CT is a valuable tool for identifying patients likely to benefit from salvage radiotherapy, potentially ...
The Global Radiopharmaceutical Trial Finder, a new AI-powered platform, helps researchers, clinicians, and patients discover clinical trials for life-changing nuclear medicine procedures. The platform uses real-time global trials data and streamlines the trial participation process.
Researchers developed a radiotracer targeting CD24 protein on liver tumor cells, accurately detecting tumors in mice. PSMA PET/CT scans also tracked prostate cancer spread in patients, predicting shorter survival for those with interlesional progression.
A first-in-human study found that naloxone reduces opioid receptor availability by 40-50 percent in brain regions, but shows a greater reduction in women compared to men. This suggests sex-based differences in how men and women respond to opioid overdose treatments.
A new study found that long COVID patients with abnormal cardiopulmonary PET/MR findings are at a higher risk of developing heart and lung diseases. The study included 98 patients with persistent cardiopulmonary symptoms after initial COVID infection and showed significant abnormalities in both PET/MRI and dual-energy CT scans.
A new brain imaging benchmark may improve how researchers classify biologically meaningful changes associated with Alzheimer’s disease. Researchers found a tau cut-point that distinguished individuals with cognitive impairment from those aging normally, but its effectiveness was limited in non-Hispanic Black participants.
The Society of Nuclear Medicine and Molecular Imaging's Annual Meeting featured over 120 continuing education sessions on innovations in oncology, neurology, and cardiology. The meeting also showcased cutting-edge technology, including AI, theranostics, and novel imaging probes.
A new PET/CT imaging technique visualizes activated fibroblasts in the heart muscle, detecting multiple forms of cardiomyopathy. The method provides valuable insights into disease progression and helps improve risk stratification for patients with non-ischemic cardiomyopathy.
A novel PET imaging approach can accurately detect and monitor Mycobacteroides abscessus lung infections. The technique uses 11C-PABA PET to differentiate between bacterial infection and inflammatory diseases.
A study found that modifiable risk factors like education, BMI, and hypertension can slow down the spread of Alzheimer's tau tangles. The research suggests that modifying these risk factors can help delay disease progression.
A novel molecular imaging agent targeting glypican-3 has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter. The agent provides high-contrast images of GPC3-positive liver tumors, offering a promising new tool for early diagnosis and staging of HCC.
Researchers used PET imaging to map brain inflammation in PAOS patients, finding distinct patterns that correlate with tau pathology and Parkinson-plus syndrome. The study provides new insights into neuroinflammation's role in disease progression and may lead to earlier diagnosis and targeted treatments.
A new PET radiotracer can detect a wide range of mold species linked to life-threatening infections in cancer and transplant patients. The imaging agent, 18F-FDS, has the potential to dramatically enhance diagnosis and monitoring of invasive mold infections.
A new peptide-based PET tracer outperforms FDG PET in measuring PD-L1 expression in head and neck cancers. The tracer's uptake strongly correlates with PD-L1 levels, suggesting its potential for personalized treatment strategies.
Researchers developed a novel PET tracer targeting phosphodiesterase 4B to visualize real-time brain inflammation. The tracer showed superior image quality and greater brain distribution compared to existing tracers, highlighting its potential for early diagnosis and personalized therapy in neurodegenerative diseases.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has selected 7 new Fellows for their exceptional achievements in the field. The SNMMI Fellowship is a prestigious recognition of outstanding service to the society and excellence in scientific discovery, educational efforts, or clinical practice.
Wynn Volkert, a renowned expert in nuclear medicine, has been awarded the 2025 SNMMI Georg Charles de Hevesy Nuclear Pioneer Award. He made significant contributions to radiopharmaceutical development, including FDA-approved agents for brain and bone imaging.
Cybil Nielsen has been elected as the new president of the SNMMI Technologist Section, with a focus on expanding educational programs, mentorship opportunities, and networking events. She aims to promote the recognition and advancement of nuclear medicine technologists within the healthcare landscape.
Shannon Youngblood, a seasoned nuclear medicine professional, has been elected as President-Elect of the SNMMI Technologist Section. She aims to elevate visibility and recognition for nuclear medicine professionals through advocacy, promote diversity and inclusion in the workforce, and advance education and professional development. Wi...
A newly developed cardiac PET imaging technique offers a simpler way to detect significant coronary artery disease by eliminating the need for complex scanning protocols. The technique has been shown to accurately estimate myocardial flow reserve during both exercise and pharmacologic stress, making advanced heart imaging more accessible.
A novel integrated molecular imaging approach using dual PET/MR and PET/CMR techniques enables precise localization of heart damage and accurate identification of disease subtypes. This method also provides direct evidence supporting surgery as a cardio-protective intervention in patients with primary aldosteronism.
A new brain imaging platform combining upright PET scanning, AR eye tracking, and motion tracking enables researchers to study brain function in a more natural and dynamic way. This approach offers a more realistic view of brain activity, holding promise for earlier detection of cognitive disorders.
Advanced software is used to measure radiation dose distribution throughout the body, ensuring patient safety and tailoring treatments. Post-therapy imaging helps identify complications and guide clinical decisions, ultimately optimizing treatment outcomes and protecting patients.
Two new PET imaging agents have been developed to identify the histamine H3 receptor, which regulates learning, memory, and sleep. These novel tracers show high brain uptake, excellent specificity, and improved in vivo stability.
A new PET imaging technique has successfully visualized three radiotracers in a single scan, enabling a more comprehensive molecular profile of disease. This innovation offers the potential to deliver greater precision in both diagnosis and therapeutic assessment, particularly for complex diseases like cancer.
Researchers found that low blood flow at rest may predict heart failure or death, while low stress flow may indicate heart attack risk. A new PET scan method also showed promise for Alzheimer's detection with high accuracy and minimal discomfort.
A novel immuno-PET/CT imaging technique has identified a potent biomarker for nasopharyngeal cancer (NPC), CD70, which is highly expressed in NPCs. The technique showed 100% detection rate of primary tumors and 93% detection rate of local lymph node metastasis in patients with early-stage disease.
Research found that approximately 50% of participants with late-life depression and bipolar disorder showed tau accumulation in their brains, compared to only about 15% of healthy controls. The study suggests that neurodegenerative diseases, including Alzheimer's, can initially manifest as psychiatric symptoms.